Minerva Neurosciences (NERV) Cash & Equivalents (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Cash & Equivalents data on file, last reported at $32.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 88.89% year-over-year to $32.7 million; the trailing twelve-month figure through Mar 2026 stood at $32.7 million (up 88.89% YoY), and the FY2025 full-year result was $82.3 million, up 285.27% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $32.7 million, down from $82.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $82.3 million in Q4 2025 and bottomed at $12.3 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $34.8 million (2024), against an average of $37.0 million.
• Peak annual rise in Cash & Equivalents reached 285.27% in 2025, while the deepest fall reached 53.69% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $34.6 million in 2022, then grew by 18.39% to $40.9 million in 2023, then slumped by 47.79% to $21.4 million in 2024, then soared by 285.27% to $82.3 million in 2025, then plunged by 60.32% to $32.7 million in 2026.
• The last three Cash & Equivalents figures came in at $32.7 million (Q1 2026), $82.3 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.

Peer Comparison